請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/99818完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 吳從周 | zh_TW |
| dc.contributor.advisor | Chung-Jau Wu | en |
| dc.contributor.author | 楊敏儷 | zh_TW |
| dc.contributor.author | Min-Li Yang | en |
| dc.date.accessioned | 2025-09-18T16:05:59Z | - |
| dc.date.available | 2025-09-19 | - |
| dc.date.copyright | 2025-09-18 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-07-28 | - |
| dc.identifier.citation | 一、中文部分(依作者姓氏筆畫順序排列)
(一)書籍 1. 吳麥斯、張偉嶠、張連成、李倍慈、廖啟志、林世嘉、吳宜瑾、李郁雯、吳全峰、劉宏恩、林滿玉、黃韻如、林曉慧、蔡甫昌、陳沛隆、沈家寧、林頌然、林琬琬、劉燦宏、邱宗傑、蘇嘉瑞、程馨(2024),《我國再生醫療未來發展之挑戰》,財團法人中技社。 2. 林世嘉(2020),《未來醫療-再生醫療發展與趨勢》,台北市:財團法人台灣醫界聯盟基金會。 3. 資誠聯合會計師事務所(2023),《再生醫療挑戰與機會:從背負眾望走向願景成真之路》。 4. 經濟部產業發展署(2024),《2024生技產業白皮書》。 (二)期刊 1. 李昕、宋曉亭(2017),「日本再生醫療法律制度評述」,《國外社會科學》,第3期,頁125-135。 2. 李倍慈(2020),「人類細胞製劑的製造與管控考量-以美國、歐盟與日本核准上市之產品為例」,《當代醫藥法規月刊》,第122期,頁1-16。 3. 張碩修(2016),「美國FDA於2015年10月發表「人類細胞/組織相關產品之同源使用」指引草案」,《當代醫藥法規月刊》,第65期,頁21-23。 4. 黃三榮(2016),「淺論日本「再生医療等の安全性の確保等に関する法律」」,《萬國法律》,第209期,頁2-16。 5. 劉宏恩(2013),「生物醫學的產學合作、利益衝突與公眾信賴-從人體研究法的相關規定及一項台灣社會調查談起」,《月旦法學》,第215期,頁17-31。 6. 蔡甫昌、許哲銘、莊宇真(2024),「再生醫療發展爭議案例與我國倫理法規現況探討」,《台灣醫學》,第28卷6期,頁699-708。 7. 臺大醫院公共事務室(2016),「臺大醫院收治八仙塵爆傷患醫療成果說明」,《臺大醫院健康電子報》,第98期。 二、英文部分 1. Akgun, I., Unlu, M. C., Erdal, O. A., Ogut, T., Erturk, M., Ovali, E., Kantarci, F., Caliskan, G., and Akgun, Y. (2015), “Matrix-induced Autologous Mesenchymal Stem Cell Implantation Versus Matrix-induced Autologous Chondrocyte Implantation in the Treatment of Chondral Defects of the Knee: a 2-year Randomized Study,” Archives of Orthopaedic and Trauma Surgery, 135(2), pp.251-263. 2. Arnold, C. (2021), “Record Number of Gene-therapy Trials, Despite Setbacks.” Nature Medicine, 27(8), pp.1312-1315. 3. Cao ZM, Kong FS, Ding JQ, Chen CX, He FM and Deng WB (2024), “Promoting Alzheimer’s Disease Research and Therapy with Stem Cell Technology,” Stem Cell Research and Therapy, 15(1). 4. De Gioia, R., Biella, F., Citterio, G., Rizzo, F., Abati, E., Nizzardo, M., Bresolin, N., Comi, P. C. and Corti, S. (2020), “Neural Stem Cell Transplantation for Neurodegenerative Diseases,” International Journal of Molecular Sciences, 21(9). 5. Goula, A., Gkioka, V., Michalopoulos, E., Katsimpoulas, M., Noutsias, M., Sarri, E. F., Stavropoulos, C. and Kostakis, A. (2020), “Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine,” Journal of Clinical Medicine Research, 12(12), pp.780-786. 6. Hsiao LC, Lin YN, Shyu WC, Ho M, Lu CR, Chang SS, Wang YC, Chen JY, Lu SY, Wu MY, Li KY, Lin YK, Tseng WI, Su MY, Hsu CT, Tsai CK, Chiu LT, Chen CL, Lin CL, Hu KC, Cho DY, Tsai CH, Chang KC, Jeng LB (2022), “First-in-human Pilot Trial of Combined Intracoronary and Intravenous Mesenchymal Stem Cell Therapy in Acute Myocardial Infarction,” Frontiers in Cardiovascular Medicine, pp.1-17. 7. IQVIA Institute for Human Data Science (2022), The Global Use of Medicines2022-Outlook to 2026. 8. Lian XF, Lu DH, Liu HL, Liu YJ, Han XQ, Yang Y, Lin Y, Zeng QX, Huang ZJ, Xie F, Huang CH, Wu HM, Long AM, Deng LP, Zhang F (2022), “Effectiveness and Safety of Human Umbilical Cord-mesenchymal Stem Cells for Treating Type 2 Diabetes Mellitus,” World Journal of Diabetes, 13(10), pp.877-887. 9. Nadel, L. (2021), “The Future of Stem Cell Therapy Regulation Under the FDA’s Comprehensive Regenerative Medicine Policy Framework Through a Public Health Lens,” Houston Journal of Health Law and Policy, 21(1), pp.263-268. 10. Romain, P. L. (2015), “Conflicts of Interest in Research: Looking out for Number One Means Keeping the Primary Interest Front and Center,” Current Reviews in Musculoskeletal Medicine, 8(2), pp.122-127. 11. Tunis, S., Hanna, E., Neumann, P. J., Toumi, M., Dabbous, O., Drummond, M., Fricke, F-U, Sullivan, S. D., Malone, D. C., Persson, U. and Chambers, J. D. (2021), “Variation in Market Access Decisions for Cell and Gene Therapies across the United States, Canada, and Europe,” Health Policy, 125(12), pp.1550-1556. 12. Volokh, E. (2007), “Medical Self-Defense, Prohibited Experimental Therapies, and Payment for Organs,” Harvard Law Review, 120(7), pp.1813-1846. 13. Wang MY, Xu XX, Lei XX, Tan J, Xie HQ (2021), “Mesenchymal Stem Cell-based Therapy for Burn Wound Healing,” Burns and Trauma, Vol.9, pp.1-16. 三、網路部分 1. 王芊淩、黃浩珉(2024),「30年最大醫院護理師出走潮-病房關床、手術限時、急診打結,動搖國本的護理荒」,《報導者》,https://www.twreporter.org/a/data-reporter-health-emergency-nursing-shortage。 2. 方明(2023),「再生醫療雙法真可救命?還是買希望?」,《工商時報》,9月28日,https://www.ctee.com.tw/news/20230928701137-430504。 3. 日本再興戦略-JAPAN is BACK,https://www.kantei.go.jp/jp/singi/keizaisaisei/pdf/saikou_jpn.pdf。 4. 杜蕙蓉(2022),「再生醫療三法 掀千億商機」,《工商時報》,4月25日,https://www.ctee.com.tw/news/20220425700126-430504。 5. 吳培安(2021),「細胞治療《特管辦法》上路三年 破百件 成效分析仍難產?!」,《環球生技》,https://news.gbimonthly.com/tw/article/show.php?num=45563。 6. 財團法人中華民國消費者文教基金會(2024),「細胞治療法帶來的是希望還是失望? 消基會呼籲公開透明細胞療法的實際成效 免讓病患家屬傷心又傷財」,https://www.consumers.org.tw/product-detail-3796173.html。 7. 張鴻仁(2024),「當健保總額遠追不上新藥進展,商保補健保外還能有什麼選項?」,《報導者》,https://www.twreporter.org/a/opinion-national-health-insurance-under-global-budget-payment-system。 8. 陳潔(2023),「檯面上700例、實際執行超過7萬例-揭開細胞治療地下化生態」,《報導者》,https://www.twreporter.org/a/regenerative-medicine-fraud。 9. 溫桂香(2023),「推再生醫療立法 總統:讓生技成為下一個兆元產業」,《中央通訊社》,2月23日,https://www.cna.com.tw/news/aipl/202302230070.aspx。 10. 葉明叡、郭年真(2024),「健保又不給付了,為什麼「健保協同商保」恐有反效果?」,《報導者》,https://www.twreporter.org/a/opinion-public-and-private-health-insurance。 11. 葉雲卿、張連成(2021),「藥品試用權 Right to Try Act-由美國與中國醫藥相關法規改革談起」,《北美智權報》,第280期,https://www.naipo.com/Portals/1/web_tw/Knowledge_Center/Laws/IPNC_210310_0202.htm。 12. 趙于婷(2023),「再生醫療費用昂貴!薛瑞元:擬納入健保、商保」,《ETtoday新聞雲》,3月20日,https://health.ettoday.net/news/2463003%23ixzz8vltx4q8W。 13. Allie, N. (2022), “Patient Death Following CAR-T Therapy Highlights Serious Manufacturing Issues,” Pharmaceutical Technology, https://www.pharmaceutical-technology.com/news/patient-death-following-car-t-therapy-manufacturing/. 14. BT戦略会議(2002),「バイオテクノロジー戦略大綱」,https://www.dl.ndl.go.jp/view/prepareDownload?itemId=info%3Andljp%2Fpid%2F3531296&contentNo=1。 15. Cavazzoni, P. (2022), “FDA User Fee Reauthorization: Ensuring Safe and Effective Drugs and Biologics,” U.S. Food and Drug Administration, https://www.fda.gov/news-events/congressional-testimony/fda-user-fee-reauthorization-ensuring-safe-and-effective-drugs-and-biologics-02032022. 16. International Council of Nurses (2023), “ICN Report Says Shortage of Nurses is a Global Health Emergency,” https://www.icn.ch/news/icn-report-says-shortage-nurses-global-health-emergency. 17. Maziarz, R. T. (2019), “CAR T-cell therapy total cost can exceed $1.5 million per treatment,” Healio, https://www.healio.com/news/hematology-oncology/20190529/car-tcell-therapy-total-cost-can-exceed-15-million-per-treatment. 18. Murdock, C. J. and Laurencin, C. T. (2017), “FDA Announces Policy Framework to Develop Regenerative Medicine Products,”https://www.researchgate.net/publication/340362206_FDA_announces_policy_framework_to_develop_regenerative_medicine_products. 19. Pinsent Masons (2022), “Evolving EU policy on cell and gene therapies needs views of business,” https://www.pinsentmasons.com/out-law/analysis/evolving-eu-policy-on-cell-and-gene-therapies-needs-views-of-business. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/99818 | - |
| dc.description.abstract | 隨著近年來再生醫療之技術與製藥的不斷創新和研發,為許多在既有醫療手段下無法獲得良好治療成效的急重症(尤其是癌症)病患開啟了一扇新的希望之門,再生醫療的產業發展前景普遍被世人看好。惟再生醫療屬於新興生醫科技領域,不僅其創新研發之過程可能因涉及倫理議題而引發廣泛爭議與討論之外,又因為一般民眾對於再生醫療的知識普遍不足,導致醫病之間存在嚴重的資訊不對稱問題,因此近年來世界多數國家均曾發生不肖分子利用再生醫療進行詐騙的事件。為了保障病患權益,讓再生醫療產業健全發展,多數醫療先進國家均紛紛對再生醫療進行相關立法。
本研究首先對再生醫療法進行政策分析,說明政策目標以及法律和產業的協同發展,進而對再生醫療進行概述,包括技術基礎、法律範疇與重要性,以及面臨的發展與挑戰,並透過國際立法和台灣法規的比較來說明再生醫療的相關法律框架。此外,亦從技術與安全、倫理議題、商業化與監管等角度來探討再生醫療的法律與倫理挑戰。 最後,彙整上述對再生醫療法的各項討論與分析結果,提出本研究的研究結論與研究建議。 | zh_TW |
| dc.description.abstract | With the continuous innovation and research and development of regenerative medicine technology and pharmaceuticals in recent years, a new door of hope has been opened for many patients with acute and severe diseases (especially cancer) who cannot obtain good treatment results with existing medical methods, and the development prospects of the regenerative medicine industry are generally optimistic.
However, regenerative medicine belongs to the emerging field of biomedical technology. Its innovative research and development process may cause widespread controversy and discussion due to the ethical issues involved. In addition, the general public's knowledge of regenerative medicine is generally insufficient, resulting in serious information asymmetry between doctors and patients. Therefore, in recent years, unscrupulous elements have used regenerative medicine to commit fraud in most countries in the world. In order to protect patients’ rights and allow the sound development of the regenerative medicine industry, most medically advanced countries have enacted relevant legislation on regenerative medicine. This study first conducts a policy analysis of the Regenerative Medicine Act, explaining the policy objectives and the coordinated development of the law and industry. It then provides an overview of regenerative medicine, including its technical basis, legal scope and importance, as well as the development and challenges it faces. It also explains the relevant legal framework for regenerative medicine through a comparison of international legislation and Taiwan regulations. In addition, the legal and ethical challenges of regenerative medicine are discussed from the perspectives of technology and safety, ethical issues, commercialization and regulation. Finally, based on the above discussions and analysis results of regenerative medicine, the conclusions and suggestions of this study are put forward. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2025-09-18T16:05:59Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2025-09-18T16:05:59Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 謝誌 i
中文摘要 ii Abstract iii 目次 iv 圖次 vi 表次 vii 第一章 緒論 1 第一節 研究背景與研究動機 1 第二節 研究問題與研究目的 4 第三節 研究架構與研究流程 5 第四節 研究方法 6 第二章 再生醫療法的政策分析 7 第一節 政策目標 7 第二節 法律與產業協同發展 9 一、政府對產業的監管與協助 9 二、國際合作與標準化 11 第三章 再生醫療法概述 13 第一節 再生醫療的技術基礎 13 一、細胞治療 13 二、基因治療 14 三、組織工程 14 第二節 法律範疇與重要性 16 一、衛福部主管部分 16 二、經濟部主管部分 17 第三節 再生醫療的發展與挑戰 19 一、產業鏈 19 二、應用範疇 20 三、面對挑戰 23 第四章 再生醫療相關法律框架 27 第一節 國際立法比較 27 一、日本 27 二、歐盟 32 三、美國 37 四、南韓 45 五、國際比較 48 第二節 台灣法規 50 一、緣起 50 二、現行法規 52 第五章 法律與倫理挑戰 56 第一節 技術與安全 56 第二節 倫理議題 58 一、病患知情同意 58 二、健康資源分配之公平性 59 第三節 商業化與監管 60 第四節 損害賠償 63 第六章 結論與建議 66 第一節 研究結論 66 第二節 研究建議 68 一、強化資訊透明度,建立社會信任 68 二、推動跨領域專業培訓和公眾教育 69 三、徹底落實違法案件稽查 70 參考文獻 71 | - |
| dc.language.iso | zh_TW | - |
| dc.subject | 資訊不對稱 | zh_TW |
| dc.subject | 再生醫療 | zh_TW |
| dc.subject | 再生醫療法 | zh_TW |
| dc.subject | 倫理議題 | zh_TW |
| dc.subject | 病患權益 | zh_TW |
| dc.subject | Patients’ rights | en |
| dc.subject | Ethical issues | en |
| dc.subject | Regenerative medicine act | en |
| dc.subject | Information asymmetry | en |
| dc.subject | Regenerative medicine | en |
| dc.title | 再生醫療法規範與探討: 倫理、法律與政策的跨域探討 | zh_TW |
| dc.title | Regulations and Discussions on Regenerative Medicine Law: Cross-disciplinary Discussion of Ethics, Law and Policy | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 113-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 向明恩;邱琦 | zh_TW |
| dc.contributor.oralexamcommittee | Ming-En Hsiang;Chi Chiu | en |
| dc.subject.keyword | 再生醫療,資訊不對稱,病患權益,倫理議題,再生醫療法, | zh_TW |
| dc.subject.keyword | Regenerative medicine,Information asymmetry,Patients’ rights,Ethical issues,Regenerative medicine act, | en |
| dc.relation.page | 74 | - |
| dc.identifier.doi | 10.6342/NTU202502669 | - |
| dc.rights.note | 未授權 | - |
| dc.date.accepted | 2025-07-30 | - |
| dc.contributor.author-college | 進修推廣學院 | - |
| dc.contributor.author-dept | 事業經營法務碩士在職學位學程 | - |
| dc.date.embargo-lift | N/A | - |
| 顯示於系所單位: | 事業經營法務碩士在職學位學程 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-113-2.pdf 未授權公開取用 | 2.78 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
